Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, British Columbia, Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new ...
| Ticker |
Sentiment |
Impact |
|
JAZZ
|
Neutral
|
2 %
|
|
BGNE
|
Neutral
|
6 %
|
